Ziprasidone Study Guide
Question
Create a study guide for your assigned psychotropic medication agents. Your study guide should be in the form of an outline with references, and you should incorporate visual elements such as concept maps, charts, diagrams, images, color coding, mnemonics, and/or flashcards. Be creative! It should not be in the format of an APA paper. Your guide should be informed by the FDA-approved and Evidenced-Based, Clinical Practice Guidelines Research but also supported by at least three other scholarly resources.
Areas of importance you should address, but are not limited to, are:
Title page
Description of the Psychopharmacological medication agent including brand and generic names and appropriate FDA indication uses
Any supporting, valid and reliable research for non-FDA uses
Drug classification
The medication mechanism of action
The medication pharmacokinetics
The medication pharmacodynamics
Mechanism of Action
Appropriate dosing, administration route, and any considerations for dosing alterations
Considerations of use and dosing in specific specialty populations to consider children, adolescents, elderly, pregnancy, suicidal behaviors, etc.
Definition of Half-life, why half-life is important, and the half-life for your assigned medication
Side effects/adverse reaction potentials
Contraindications for use including significant drug to drug interactions
Overdose Considerations
Diagnostics and labs monitoring
Comorbidities considerations
Legal and ethical considerations
Pertinent patient education considerations
Reference Page


Solution
Ziprasidone Study Guide
Description
Ziprasidone is an atypical antipsychotic medication approved by the Food and Drug Administration (FDA) for treating schizophrenia and acute bipolar mania. It is a serotonin-dopamine antagonist classified as a second-generation antipsychotic (SGA). It has both dopamine type-2 (D2) and serotonin type-2 (5-HT2) receptor-blocking properties, which allows it to reduce positive and negative symptoms of schizophrenia, as well as agitation and depression (Coralic et al., 2022). Ziprasidone is prescribed to adults, adolescents, and children ten years or older for treating schizophrenia and acute manic or mixed episodes associated with bipolar disorder. It is commonly marketed under the brand name Geodon but is also available in generic form.
Ziprasidone Monograph for Professionals - Drugs.com
Extracted from: https://www.drugs.com/images/pills/fio/GSO20010.JPG
Description of the Psychopharmacological medication agent, including brand and generic names and appropriate FDA indication, uses
Generic Name: Ziprasidone
Brand Name: Geodon
Extracted from: https://www.marylandmalpracticecenter.com/wp-content/uploads/2015/01/geodon.jpg
FDA Indications Uses
Geodon has been approved by the U.S. Food and Drug Administration (FDA) for treating schizophrenia and acute manic or mixed episodes associated with bipolar disorder in adults, adolescents, and children ten years or older.
Non-FDA Uses
● Ziprasidone has been studied as an adjunctive therapy to treat bipolar disorder, schizophrenia, and other psychiatric disorders and as a potential treatment for autism spectrum disorder, Tourette syndrome, and agitation in dementia patients. Results from studies have been mixed but generally suggest that ziprasidone may be beneficial in some cases (Wozniak et al., 2022).
● Studies have suggested that Ziprasidone may also effectively treat major depression as an adjunct therapy to antidepressants. Further randomized placebo-controlled trials are needed to substantiate this use.
● Studies have demonstrated that ziprasidone may effectively treat behavioral disturbances associated with dementia in elderly patients.
● Ziprasidone has also been shown to reduce symptoms of aggression, agitation, and irritability in pediatric patients.
● Also, studies suggest that Ziprasidone may effectively treat anxiety disorders such as social anxiety, panic disorder, and posttraumatic stress disorder (PTSD) (Tashan, Karakucuk, & Celebi, 2019).
Extracted from: https://encrypted-tbn0.gstatic.com/images?q=tbn:ANd9GcQAPl-L_H60IQ56G8MbZ88Hvb7peTidRkV4dA&usqp=CAU
Research Supporting Non-FDA Uses
A systematic review by Wozniak et al. (2022) found that ziprasidone was significantly better than a placebo in improving depressive symptoms when used as an adjunct to antidepressant treatment. This finding suggests that it may be useful in treating major depression as an adjunct therapy to antidepressants. Another systematic review by Younce, Davis, & Black (2019) found that ziprasidone may effectively treat anxiety disorders such as social anxiety, panic disorder, and PTSD. However, further research is needed to substantiate this finding.
Drug Classification
Ziprasidone is a second-generation antipsychotic belonging to the benzisoxazole class of drugs yet is chemically unrelated to other antipsychotics on the market (Martel et al., 2021).
Extracted from:
The medication mechanism of action
Ziprasidone is an atypical antipsychotic that blocks certain brain receptors, including serotonin, dopamine, and norepinephrine. It is believed to help regulate chemical imbalances in the brain that may be responsible for symptoms of mental disorders like schizophrenia, bipolar disorder, and certain depressive disorders. Ziprasidone works by blocking the action of certain chemicals in the brain called neurotransmitters. It is thought to be due to its ability to block receptors that respond to dopamine and serotonin (Younce, Davis, & Black, 2019). Ziprasidone works by blocking the action of dopamine and other neurotransmitters in the brain. It is believed to work by blocking the reuptake of dopamine and serotonin and inhibiting the action of acetylcholine, histamine, and other neurotransmitters.
Ziprasidone, a second-generation antipsychotic drug, triggers a macrophage inflammatory response in vitro. Extracted from: https://ars.els-cdn.com/content/image/1-s2.0-S1043466617303319-fx1.jpg
The medication pharmacokinetics
Ziprasidone has a long half-life of about 7 hours and is rapidly metabolized by the liver via a series of enzymes. The active metabolites are excreted primarily through the kidneys. Ziprasidone is absorbed quickly in the gastrointestinal tract and is rapidly distributed throughout the body. It has a half-life of approximately 7-8 hours (Tashan, Karakucuk, & Celebi, 2019).
Pharmacodynamics
Ziprasidone is an atypical antipsychotic medication that works by blocking D2 dopamine receptors in the brain and other receptors, including serotonin, histamine, and muscarinic acetylcholine. This action helps to reduce psychotic symptoms such as hallucinations, delusions, and disorganized thinking. The mechanism of action and pharmacodynamics Ziprasidone is a serotonin-dopamine antagonist that works by blocking dopamine type-2 (D2) and serotonin type-2 (5-HT2) receptors in the brain (Martel et al., 2021). This action helps to reduce positive and negative symptoms of schizophrenia, as well as agitation and depression associated with bipolar mania.